Article in the Australian discussing the futures of various biotech companies. Avexa described as a potential 20-bagger and woefully undervalued.... but also at risk of going out the back door.
http://www.theaustralian.news.com.au/story/0,25197,24441506-5001942,00.html
Add to My Watchlist
What is My Watchlist?